RIVIA Expands Scientific Leadership with the Appointment of Tristan Heintz as Scientific Expert

Zurich, Switzerland – 10 Oct 2025 – RIVIA, the clinical trial intelligence company, today announced the appointment of Tristan Heintz, PhD as Scientific Expert, reinforcing its commitment to scientific rigor and data-driven innovation in clinical development.

Tristan brings extensive experience in translational research and early-stage drug discovery, with a strong background in bridging discovery science and data analytics. Before joining RIVIA, he served as Chief Scientist Officer at Rejuveron Vascular Therapeutics and then co-founded Barriera Therapeutics, where he helped translate complex biological data into actionable insights for therapeutic development.

“Tristan’s expertise in translational science and data interpretation will be invaluable as we continue to expand Rivia’s intelligence platform,” said Erik Scalfaro, CEO and co-founder of RIVIA. “His scientific perspective will help ensure our solutions remain both rigorous and relevant for our biotech partners.”

As Scientific Expert, Tristan will work closely with RIVIA’s product, data science, and customer teams to strengthen analytical frameworks and foster collaborations with innovative biotech sponsors.

“I’m delighted to contribute to RIVIA’s mission to make clinical and translational data more accessible and actionable,” said Tristan Heintz. “RIVIA’s vision to unify trial intelligence across systems and teams aligns closely with my passion for accelerating the path from data to insight.”

About RIVIA
RIVIA is building the clinical trial intelligence platform that unifies data from across sources in real time—from EDC, labs, imaging, and more—into trial workflows and strategic decisions. By combining zero-fault reliability with advanced analytics, Rivia empowers biotechs to accelerate development and deliver life-changing therapies.

‍